Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immunogenicity of the VPM1002 vaccine versus BCG in HIV-exposed and unexposed newborns in South Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• VPM1002 (recombinant Bacillus Calmette-Guérin vaccine (rBCG))

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED